Skip to Content
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 04/26/17

Programs & Resources

  • The Cancer Imaging Program has been creating Investigational New Drug Applications (IND) for imaging agents in order to engage in multi-center clinical trials of these materials. A subset of the documents filed is being made available to the research community to implement routine synthesis of tracers at their own facilities and to assist investigators with the filing of their own INDs. The document sets available are for F-18 fluorothymidine (FLT), F-18 FMISO, and F-18 FES.
  • The Cancer Imaging Archive (TCIA) is provided by the Cancer Imaging Program (CIP) as a service to the research community. TCIA provides a freely accessible, open archive of cancer-specific medical images and metadata accessible for public download. A huge amount of clinical and research images are collected each year with many high value data sets already available. TCIA organizes and catalogs the images so that they may be used for a variety of purposes.

The CIP IND Directory is a centralized resource to facilitate the sharing of IND information. If you have an IND for an imaging agent, you are welcome to provide some or all of the following information to for inclusion in the directory:

  • Agent Name (required)
  • IND# (posting the IND# is optional, but you must confirm that an approved IND is in place)
  • Contact Institution (required)
  • Contact (you may provide a direct email address, refer to a publication, or have inquiries directed to CIP)
  • Source DOC Issue Date (year of publication, or investigator communication with CIP)
  • Source Documentation (publications that refer to IND, or other investigator communications)
  • (NCT numbers for clinical trials associated with your IND agent)
  • Synonyms (optional)

Additional Resources

The NCI-Frederick Small Animal Imaging Program was established to provide NCI Investigators with a state-of-the-art In Vivo imaging facility. It has been operational since October 2006. Capabilities include optical imaging, ultrasound, magnetic resonance imaging and positron emission tomography and access to a range of appropriate contrast agents.